Postepy Dermatologii I Alergologii最新文献

{"title":"Exploring skin picking disorder: aetiology, treatment, and future directions.","authors":"Hamad Alfahaad, Majed Aldehri, Soliman Ayed Alsaiari, Fayeh Asiri, Mahdi Alfataih, Saeed Alahmari","doi":"10.5114/ada.2024.142579","DOIUrl":"10.5114/ada.2024.142579","url":null,"abstract":"<p><p>Skin picking disorder (SPD) is a psychiatric condition characterized by repetitive picking of the skin, causing damage to tissue and significant distress. Despite its prevalence and impact, SPD remains understudied and often overlooked in clinical practice. This review thoroughly examines SPD, including its epidemiology, aetiology, clinical presentation, methods of treatment, challenges, and future directions. The review highlights the multifactorial nature of SPD, involving genetic, neurobiological, and psychological factors. Clinical presentation of SPD includes compulsive skin picking behaviours, emotional distress, and impaired social functioning. This review underscores the importance of recognizing and addressing SPD, emphasizing the need for integrated approaches to assessment, treatment, and research. By advancing our understanding of SPD, we can improve outcomes and quality of life for individuals affected by this disorder.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"41 6","pages":"545-551"},"PeriodicalIF":1.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11770568/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143061585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regulation of involucrin and signalling pathway in scleroderma epidermal keratinocytes.","authors":"Jia-Qi Chen, Min Zheng, Wei Li, Jiong Zhou, Xiao-Yong Man","doi":"10.5114/ada.2024.144841","DOIUrl":"10.5114/ada.2024.144841","url":null,"abstract":"<p><strong>Introduction: </strong>Systemic sclerosis is a complex disease characterized by the fibrosis and vasculopathy.</p><p><strong>Aim: </strong>We aimed to assess scleroderma by examining involucrin, an early terminal differentiation marker of epidermal keratinocytes.</p><p><strong>Material and methods: </strong>Immunolocalization of involucrin was performed in healthy controls and patients with scleroderma lesions by using an immunofluorescence (IF) assay. Normal and scleroderma keratinocytes were incubated in low-Ca basal-defined K-SFM overnight. Cells were pre-treated with Y-27632 (a Rho signalling pathway inhibitor) or interleukins (ILs), tumor necrosis factor-α (TNF-α), transforming growth factor β1 (TGF-β1), endothelin-1 (ET-1), interferon-γ (IFN)-γ, vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) - BB. The involucrin protein expression level was measured by western blot.</p><p><strong>Results: </strong>Compared with the normal skin, involucrin was detected in the granular layer and the upper stratum spinosum in patients with scleroderma lesions. However, involucrin protein expression was decreased in cultured scleroderma keratinocytes. IL-6, IL-10, IL-17A, TNF-α, TGF-β1, ET-1, IFN-γ, VEGF165, and PDGF-BB increased involucrin expression in normal keratinocytes but decreased it in scleroderma keratinocytes. IFN-γ and IL-13 remarkably downregulated involucrin levels in normal and scleroderma keratinocytes, respectively, by Y-27632 intervention.</p><p><strong>Conclusions: </strong>Inflammatory cytokines, such as IL-6, IL-10, TGF-β1, ET-1, IFN-γ, VEGF, PDGF-BB, and Rho signalling pathway may be associated with the delayed epidermal differentiation in scleroderma.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"41 6","pages":"604-609"},"PeriodicalIF":1.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11770575/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143060775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Significance of HLA-B*15 in three pemphigus patients with rituximab-triggered severe cutaneous drug reactions.","authors":"Tang Jun-Ting, Tu Ying, Sun Dong-Jie, Nong Xiang, Cao Can, Du Si-Cheng, Cun Yue-Ting, He Li","doi":"10.5114/ada.2024.145439","DOIUrl":"10.5114/ada.2024.145439","url":null,"abstract":"<p><strong>Introduction: </strong>Rituximab, a CD20 inhibitor, has swiftly become the primary treatment for pemphigus patients.</p><p><strong>Aim: </strong>We present 3 cases of pemphigus patients who had undergone rituximab treatment.</p><p><strong>Material and methods: </strong>After the second intravenous administration of rituximab, the primary rash developed into severe cutaneous drug reactions. Peripheral blood was collected from the aforementioned 3 patients for the detection of susceptibility genes by using second-generation sequencing.</p><p><strong>Results: </strong>Notably, a significant resemblance was observed in the HLA profiles of these 3 patients, particularly regarding high-risk alleles associated with rituximab-induced severe cutaneous drug reactions (CDRs). This rare occurrence of severe CDRs post-rituximab administration may be HLA-dependent and linked to HLA-B*15:02:01, HLA-B*15:12 and HLA-B*15:27:01. This pioneering laboratory trial shows the pathological background of rituximab-induced severe cutaneous drug reactions.</p><p><strong>Conclusions: </strong>Our findings contribute to the expanding catalogue of potential HLA-B*15 linked to severe CDRs and underscore the importance of vigilance regarding such reactions in pemphigus patients undergoing rituximab therapy.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"41 6","pages":"566-570"},"PeriodicalIF":1.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11770582/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143061177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rapid desensitization for human serum albumin (Grifols^®) hypersensitivity.","authors":"Mattia Cristallo, Federico Spataro, Nada Chaoul, Eustachio Nettis, Attilio Di Girolamo","doi":"10.5114/ada.2024.145434","DOIUrl":"10.5114/ada.2024.145434","url":null,"abstract":"","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"41 6","pages":"634-636"},"PeriodicalIF":1.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11770573/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143060589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SCALPDEX Questionnaire: creation and validation of the Polish language version.","authors":"Agnieszka Otlewska-Szpotowicz, Łukasz Matusiak, Joanna Salomon, Adam Reich, Jacek C Szepietowski","doi":"10.5114/ada.2024.142595","DOIUrl":"10.5114/ada.2024.142595","url":null,"abstract":"<p><strong>Introduction: </strong>Assessing the quality of life (QoL) in patients with various diseases is essential for understanding their well-being and guiding clinical management. Dermatological conditions, particularly those affecting the scalp, significantly impact QoL due to their visible nature, which can affect appearance and social interactions. While general QoL instruments like the Dermatology Life Quality Index (DLQI) exist, disease-specific tools like SCALPDEX are necessary for capturing the unique challenges faced by patients with scalp disorders.</p><p><strong>Aim: </strong>To translate and validate the SCALPDEX questionnaire into the Polish language to facilitate its use among Polish-speaking clinicians.</p><p><strong>Material and methods: </strong>A standard forward and backward translation procedure was used to convert the original English version of SCALPDEX into the Polish language. The validation of the Polish version was performed in a group of 60 patients with scalp dermatoses who were asked to fill in the questionnaire twice within an interval of 7 days for reassessment to evaluate test-retest reliability. During the first completion the patients were additionally asked to fill in an already existing Polish version of Dermatology Life Quality Index (DLQI), which was used as a reference questionnaire.</p><p><strong>Results: </strong>The Polish version of the SCAPLDEX questionnaire showed a very good internal consistency (Cronbach α = 0.94) and reproducibility (ICC = 0.94), with a strong correlation between SCALPDEX and DLQI scores (<i>R</i> = 0.74, <i>p</i> < 0.0001).</p><p><strong>Conclusions: </strong>The Polish version of SCALPDEX has proven to be a reliable and valid instrument for assessing the QoL in patients with scalp disorders.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"41 6","pages":"590-593"},"PeriodicalIF":1.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11770583/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143061064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Specificity and sensitivity of questionnaires in the diagnosis of allergic diseases.","authors":"Edyta Krzych-Fałta, Oksana Wojas, Filip Raciborski, Konrad Furmańczyk, Mariola Chrzanowska, Bolesław Samoliński, Agnieszka Lipiec, Barbara Piekarska, Mariusz Gujski","doi":"10.5114/ada.2024.143534","DOIUrl":"10.5114/ada.2024.143534","url":null,"abstract":"<p><strong>Introduction: </strong>Due to their widespread character, allergic diseases are a significant challenge in the field of public health and clinical practice. The available clinimetric tools, including standardized and validated questionnaires, play an important role in determining the incidence of a particular allergic disease in the targeted population.</p><p><strong>Aim: </strong>We attempted to evaluate the specificity and sensitivity of modified and standardized questions from the ISSAC and ECRHS questionnaires in the diagnosis of allergic diseases.</p><p><strong>Material and methods: </strong>We examined a total number of 1,000 respondents classified into the following age groups: 6-10, 11-15, and 16-19 years. Modified ISSAC and ECRHS questionnaires were implemented to verify the effectiveness of diagnosing allergic diseases.</p><p><strong>Results: </strong>Among individuals aged from 6 to 10 years, the specificity and sensitivity of diagnosing allergic rhinitis were 0.84 and 0.50; for asthma 0.64 and 0.85, for atopic dermatitis 0.90 and 0.42, and for food allergy 0.42 and 0.85, respectively. Respondents aged 11-15 years presented the following values of specificity and sensitivity: 0.83 and 0.46 for allergic rhinitis, 0.45 and 0.87 for asthma, 0.89 and 0.43 for atopic dermatitis, and 0.61 and 0.80 for food allergies, respectively. Finally, among patients from 16 to 19 years of age, the specificity and sensitivity of validated questionnaires as assessment tools in diagnosing allergic rhinitis were 0.91 and 0.39, for asthma 0.35 and 0.89, for atopic dermatitis 1.0 and 0.45, and for food allergy 0.67 and 0.85, respectively.</p><p><strong>Conclusions: </strong>The modified and standardized questions included in the ISSAC and ECRHS questionnaires are a valuable tool for determining the scale of allergic diseases. However, as these clinical tools are characterized by varying specificity and sensitivity, it is recommended that such tests be verified by clinical examination.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"41 6","pages":"594-603"},"PeriodicalIF":1.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11770580/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143061111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative assessment of alcaftadine and olopatadine for allergic conjunctivitis: a meta-analysis.","authors":"Xiaojuan Fu, Peijie Xu, Di Lu","doi":"10.5114/ada.2024.144166","DOIUrl":"10.5114/ada.2024.144166","url":null,"abstract":"<p><strong>Introduction: </strong>It is unclear to compare the efficacy of alcaftadine versus olopatadine for patients with allergic conjunctivitis, and this meta-analysis aims to perform the comparative assessment of their efficacy for allergic conjunctivitis.</p><p><strong>Methods: </strong>We systematically searched PubMed, Embase, Web of Science, EBSCO, and Cochrane library databases, and included randomized controlled trials (RCTs) comparing alcaftadine with olopatadine for allergic conjunctivitis. The random-effect model was used for the significant heterogeneity, and otherwise the fixed-effect model was used.</p><p><strong>Results: </strong>Twelve RCTs and 1064 patients with allergic conjunctivitis were included in this meta-analysis. In comparison with olopatadine intervention, alcaftadine intervention demonstrated a comparable ocular symptom score on 3 days (MD = -0.06; 95% CI = -0.19 to 0.07; <i>p</i> = 0.35), but was able to significantly decrease the ocular symptom score on 7 days (MD = -0.09; 95% CI = -0.16 to -0.01; <i>p</i> = 0.03), ocular symptom score on 14 days (MD = -0.25; 95% CI = -0.37 to -0.12; <i>p</i> < 0.0001) and conjunctival hyperaemia score on 14 days (MD = -0.04; 95% CI = -0.05 to -0.03; <i>p</i> < 0.00001). These two groups had similar incidence of adverse events (OR = 0.61; 95% CI = 0.34 to 1.09; <i>p</i> = 0.10).</p><p><strong>Conclusions: </strong>Alcaftadine had better capability to treat allergic conjunctivitis compared to olopatadine.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"41 6","pages":"560-565"},"PeriodicalIF":1.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11770579/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143061529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Illness acceptance among young adults with acne: a cross-sectional study.","authors":"Beata Bień, Piotr Krajewski, Jacek Cezary Szepietowski","doi":"10.5114/ada.2024.142580","DOIUrl":"10.5114/ada.2024.142580","url":null,"abstract":"<p><strong>Introduction: </strong>The level of acceptance of acne can have a substantial impact on improving patients' mood and quality of life.</p><p><strong>Aim: </strong>To investigate the level of acne vulgaris acceptance among young patients and its correlation with disease severity, quality of life, and feelings of stigmatization.</p><p><strong>Material and methods: </strong>The study was conducted on 213 young individuals diagnosed with acne. A variety of questionnaires were employed to measure the psychological aspects of the condition, including illness acceptance, quality of life, and feeling of stigmatization.</p><p><strong>Results: </strong>Based on the Global Evaluation Acne (GEA) scale, 45% of participants had mild acne, 31.7% had minimal acne, and 23.3% had moderate acne. The Acceptance of Illness Scale (AIS) scores ranged from 13 to 40, with a mean of 37.0 ±5.2 points. Males had higher illness acceptance (mean score: 37.7 vs. 36.5 points; <i>p</i> = 0.027). Most participants (87.6%) had high illness acceptance. The greatest challenge was adjusting to disease limitations. A significant negative correlation was found between acne severity and illness acceptance (<i>r</i> = -0.277<i>; p</i> < 0.001), between AIS scores and both QoL impairment (measured by the Dermatology Life Quality Index (DLQI) and the Cardiff Acne Disability Index (CADI)) (<i>r</i> = -0.499 and <i>r</i> = -0.621, respectively; <i>p</i> < 0.001 for both) as well as between AIS scores and the 6-Item Stigmatization Scale (6-ISS) (<i>r</i> = -0.621, <i>p</i> < 0.001).</p><p><strong>Conclusions: </strong>The level of acne acceptance depends on gender and the severity of acne lesions. Based on the study results, we hypothesize that an intervention aimed at increasing the level of disease acceptance could improve patients' psychological well-being and ability to cope with the condition.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"41 5","pages":"530-535"},"PeriodicalIF":1.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11589631/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142741376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma with aberrant CD56 expression: a rare case report.","authors":"Shuaihantian Luo, Yingdan Chen, Guiying Zhang","doi":"10.5114/ada.2024.144399","DOIUrl":"10.5114/ada.2024.144399","url":null,"abstract":"","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"41 5","pages":"538-541"},"PeriodicalIF":1.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11589629/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142741380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes and correlation of serum levels of interleukins 33, 15, 4, and interferon γ in children with bronchial asthma at different periods.","authors":"Liangliang Geng, Ruixue Xiao, Ke Chang","doi":"10.5114/ada.2024.143542","DOIUrl":"10.5114/ada.2024.143542","url":null,"abstract":"<p><strong>Aim: </strong>This work investigated the difference of serum cytokine levels in children with bronchial asthma (BA) in acute attack and clinical remission and the relationship between them.</p><p><strong>Material and methods: </strong>A hundred children with BA were included and enrolled into an acute attack group (AA group) and a clinical remission group (CR group) according to their medical history and clinical characteristics, with 50 children in each group. Then, another 50 healthy children in the same hospital for physical examination were randomly selected as controls.</p><p><strong>Results: </strong>Interleukin (IL) 4 (IL-4) and interferon-γ (IFN-γ) levels in the AA group were significantly higher than those in controls (<i>p</i> < 0.05), but the IL-4 and IFN-γ levels in the clinical remission phase group were not remarkably different from those in controls (<i>p</i> > 0.05). The IL-15 level in the AA group was much higher than that in children with BA in the clinical remission stage and controls, and the IL-15 level in the CR control was higher than that in controls (<i>p</i> < 0.05). IL-4 level was positively linked with INF-γ level (<i>r</i> = 15.621, <i>p</i> = 0.002) and IL-15 level (<i>r</i> = 9.581, <i>p</i> = 0.008). IL-15, IL-4, and IFN-γ were related to the incidence of BA of children and played a role in the exacerbation of respiratory inflammation during acute attacks. IL-4 was associated with IL-15 and INF-γ, and there was a synergistic relationship in promoting inflammation of BA.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"41 5","pages":"473-478"},"PeriodicalIF":1.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11589639/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142741343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}